Table 3.
Follow-Up Testing for RCLs in Subjects Infused with Gene-Modified T Cell Products
| Study No. | Principal Investigator | No. of Products Infused | No. of Subjects Infused | No. of Subjects with RCL Follow-Upa | Method of RCL Detection | Level of Sensitivity per DNA |
|---|---|---|---|---|---|---|
| 11-2 | C.H.J. | 2 | 2 | 1 | VSV-G DNA PCR | 25 copies per 1 μg |
| 11-3 | C.H.J. | 19 | 17 | 16 | VSV-G DNA PCR | 25 copies per 1 μg |
| 11-4 | C.H.J. | 2 | 2 | 2 | VSV-G DNA PCR | 25 copies per 1 μg |
| 11-11 | C.H.J. | 24 | 24 | 21 | VSV-G DNA PCR | 25 copies per 1 μg |
| 11-12 | C.H.J. | 14 | 13 | 13 | VSV-G DNA PCR | 25 copies per 1 μg |
| 11-13 | C.H.J. | 1 | 1 | 0 | VSV-G DNA PCR | 25 copies per 1 μg |
| 12-4 | C.H.J. | 36 | 36 | 34 | VSV-G DNA PCR | 25 copies per 1 μg |
| 12-16 | M.J. | 3 | 3 | 2 | VSV-G DNA PCR | 10 copies per 50 ng |
| 13-4 | C.H.J. | 32 | 32 | 23 | VSV-G DNA PCR | 25 copies per 1 μg |
| 13-12 | G.B.-S. | 31 | 31 | 24 | VSV-G DNA PCR | 5 copies per 100 ng |
| 13-15 | S.F. | 5 | 5 | 5 | VSV-G DNA PCR | 2.5 copies per 50 ng |
| 14-9 | C.H.J. | 25 | 25 | 14 | VSV-G DNA PCR | 25 copies per 1 μg |
| 14-10 | C.H.J. | 34 | 34 | 30 | VSV-G DNA PCR | 25 copies per 1 μg |
| 14-12 | C.J.T. | 76 | 76 | 49 | VSV-G DNA PCR | 10 copies per 1 μg |
| 14-18 | T.F. | 14 | 14 | 11 | VSV-G DNA PCR | 10 copies per 200 ng |
| 14-27 | S.F. | 7 | 7 | 6 | VSV-G DNA PCR | 2.5 copies per 50 ng |
| 15-9 | S.F. | 6 | 4 | 3b | VSV-G DNA PCR | 2.5 copies per 50 ng |
| 15-10 | S.F. | 6 | 6 | 5 | VSV-G DNA PCR | 2.5 copies per 50 ng |
| 15-11 | S.F. | 11 | 11 | 11 | VSV-G DNA PCR | 2.5 copies per 50 ng |
| 15-26 | M.J. | 45 | 23 | 19 | VSV-G DNA PCR | 10 copies per 50 ng |
| 15-36 | S.F. | 2 | 2 | 2 | VSV-G DNA PCR | 2.5 copies per 50 ng |
| 16-1 | M.J. | 14 | 7 | 5 | VSV-G DNA PCR | 10 copies per 50 ng |
| Total | 409 | 375 | 296 |
VSV-G, vesicular stomatitis virus G protein.
≥30 Days post-infusion.
2 subjects were tested by PCR, and 1 subject was tested by serology.